Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 -8.338M
June 30, 2026 -7.968M
March 31, 2026 -10.23M
December 31, 2025 -6.787M
September 30, 2025 -7.85M
June 30, 2025 -9.159M
March 31, 2025 53.41M
December 31, 2024 -15.06M
September 30, 2024 -11.32M
June 30, 2024 -14.73M
March 31, 2024 -21.20M
December 31, 2023 -13.96M
September 30, 2023 -18.36M
June 30, 2023 -14.37M
March 31, 2023 -20.03M
December 31, 2022 -21.94M
Date Value
September 30, 2022 -16.48M
June 30, 2022 -18.07M
March 31, 2022 -28.60M
December 31, 2021 -24.05M
September 30, 2021 -26.48M
June 30, 2021 -25.16M
March 31, 2021 -24.46M
December 31, 2020 -15.77M
September 30, 2020 -11.49M
June 30, 2020 -13.57M
March 31, 2020 -11.32M
December 31, 2019 -7.511M
September 30, 2019 -5.285M
June 30, 2019 -5.00M
March 31, 2019 -6.878M
December 31, 2018 -2.384M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.62M
Armata Pharmaceuticals, Inc. -5.516M
Voyager Therapeutics, Inc. -19.67M
Invivyd, Inc. -32.11M
Elicio Therapeutics, Inc. -10.36M